[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2603086T3 - Uso de la daptomicina - Google Patents

Uso de la daptomicina Download PDF

Info

Publication number
ES2603086T3
ES2603086T3 ES06006697.4T ES06006697T ES2603086T3 ES 2603086 T3 ES2603086 T3 ES 2603086T3 ES 06006697 T ES06006697 T ES 06006697T ES 2603086 T3 ES2603086 T3 ES 2603086T3
Authority
ES
Spain
Prior art keywords
daptomycin
dose
treatment
hours
need
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06006697.4T
Other languages
English (en)
Inventor
Frederick B. Oleson Jr.
Francis P. Tally
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cubist Pharmaceuticals LLC
Original Assignee
Cubist Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26798675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2603086(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharmaceuticals LLC filed Critical Cubist Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2603086T3 publication Critical patent/ES2603086T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

La daptomicina, para su uso en el tratamiento de una infección bacteriana en un paciente humano en necesidad del mismo, en el que una dosis para dicho tratamiento es de 10 mg/kg de daptomicina, en el que dicha dosis se administra repetidamente en un intervalo de administración de una vez cada 24 horas.

Description

Uso de la daptomicina
examinados en cada uno de cuatro perros para un total de
ES06006697.4T 1998-09-25 1999-09-24 Uso de la daptomicina Expired - Lifetime ES2603086T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10182898P 1998-09-25 1998-09-25
US101828P 1998-09-25
US12575099P 1999-03-24 1999-03-24
US125750P 1999-03-24

Publications (1)

Publication Number Publication Date
ES2603086T3 true ES2603086T3 (es) 2017-02-23

Family

ID=26798675

Family Applications (2)

Application Number Title Priority Date Filing Date
ES06006697.4T Expired - Lifetime ES2603086T3 (es) 1998-09-25 1999-09-24 Uso de la daptomicina
ES99949913T Expired - Lifetime ES2259845T3 (es) 1998-09-25 1999-09-24 Uso de la daptomicina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES99949913T Expired - Lifetime ES2259845T3 (es) 1998-09-25 1999-09-24 Uso de la daptomicina.

Country Status (26)

Country Link
US (2) US6468967B1 (es)
EP (2) EP1674107B8 (es)
JP (4) JP4184607B2 (es)
KR (2) KR20100051735A (es)
CN (2) CN1150029C (es)
AT (1) ATE322280T1 (es)
AU (1) AU764348B2 (es)
BR (1) BR9914051A (es)
CA (1) CA2344318C (es)
CY (3) CY1105556T1 (es)
DE (3) DE122006000049I1 (es)
DK (2) DK1674107T3 (es)
ES (2) ES2603086T3 (es)
HK (1) HK1040363B (es)
HU (1) HU230656B1 (es)
IS (2) IS5890A (es)
LU (1) LU91254I2 (es)
NL (1) NL300232I2 (es)
NO (1) NO20011454L (es)
NZ (1) NZ510690A (es)
PL (2) PL206091B1 (es)
PT (2) PT1674107T (es)
RU (1) RU2363489C9 (es)
SI (2) SI1115417T1 (es)
TR (1) TR200100841T2 (es)
WO (1) WO2000018419A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122006000049I1 (de) 1998-09-25 2007-01-04 Cubist Pharm Inc Verwendung von Daptomycin
CN1425025A (zh) 1999-12-15 2003-06-18 卡比斯特制药公司 作为抗菌剂的新颖的脂肽
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
KR20080036661A (ko) * 2000-12-18 2008-04-28 큐비스트 파마슈티컬즈 인코포레이티드 정제된 리포펩티드의 제조 방법
WO2002059145A1 (en) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
EP1932853A1 (en) 2001-08-06 2008-06-18 Cubist Pharmaceutical Inc. Novel depsipeptides and process for preparing same
US20040147441A1 (en) * 2002-08-23 2004-07-29 Leach Timothy S. Methods and reagents for preventing bacteremias
US20050277581A1 (en) * 2002-11-18 2005-12-15 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20050220862A1 (en) 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US20080051326A1 (en) * 2004-11-12 2008-02-28 Alexander Dylan C Antiinfective Lipopeptides
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8524735B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US20070238630A1 (en) * 2006-03-29 2007-10-11 Phillips Douglas H Subcutaneous skin cleanser
EP2018864A1 (en) 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
TW200940552A (en) * 2008-03-04 2009-10-01 Elan Pharm Inc Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens
PL2320933T3 (pl) 2008-07-17 2018-07-31 Acorda Therapeutics, Inc. Terapeutyczne dawkowanie neureguliny lub jej subsekwencji do leczenia lub profilaktyki niewydolności serca
DE102008046610A1 (de) * 2008-09-09 2010-03-11 Biomet Deutschland Gmbh Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt
ES2809177T3 (es) 2008-10-07 2021-03-03 Horizon Orphan Llc Inhalación de levofloxacino para reducir la inflamación pulmonar
KR20110091510A (ko) 2008-10-07 2011-08-11 엠펙스 파마슈티컬즈, 인코포레이티드 약동학 개선을 위한 에어로졸 플루오로퀴놀론 제형
WO2010048630A1 (en) 2008-10-24 2010-04-29 Los Angeles Biomedical Reserch Institute At Harbor-Ucla Medical Center Anti-infective hydroxy-phenyl-benzoates and methods of use
MX2011006803A (es) * 2008-12-22 2011-09-06 Cubist Pharm Inc Agentes antibacterianos novedosos para el tratamiento de infecciones gram positivas.
TW201035111A (en) 2008-12-23 2010-10-01 Biosource Pharm Inc Antibiotic compositions for the treatment of gram negative infections
US8450300B2 (en) * 2009-07-13 2013-05-28 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
CA2767614C (en) * 2009-07-13 2019-01-15 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
CA2938650C (en) 2009-09-04 2018-01-09 Raptor Pharmaceuticals Inc. Use of aerosolized levofloxacin for treating cystic fibrosis
HUE039967T2 (hu) 2009-11-23 2019-02-28 Cubist Pharmaceuticals Llc Lipopeptid kompozíció és ezzel kapcsolatos eljárások
US8247394B2 (en) 2010-06-02 2012-08-21 Cempra Pharmaceuticals Inc. Methods of treating urethritis and related infections using fusidic acid
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
US8461188B2 (en) 2011-10-20 2013-06-11 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
AU2013237939A1 (en) 2012-03-30 2014-10-30 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
WO2014041425A1 (en) * 2012-09-11 2014-03-20 Hospira Australia Pty Ltd. Daptomycin formulations and uses thereof
CN103006562B (zh) * 2013-01-21 2014-09-17 西南大学 达托霉素醇质体制剂
KR102237887B1 (ko) 2013-03-15 2021-04-07 멜린타 서브시디어리 코프. 항생제를 사용하여 과체중 및 비만 환자에서 감염을 치료하는 방법
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
JP2019515007A (ja) * 2016-05-13 2019-06-06 スペロ ポテンシエーター インコーポレイテッドＳｐｅｒｏ Ｐｏｔｅｎｔｉａｔｏｒ， Ｉｎｃ． 新規カチオン性ペプチドｓｐｒ７４１による、抗生物質活性の増強
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32455E (en) 1978-10-16 1987-07-07 Eli Lilly And Company A-21978 antibiotics and process for their production
USRE32333E (en) 1978-10-16 1987-01-20 Eli Lilly And Company A-21978 Antibiotics and process for their production
USRE32311E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
USRE32310E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4885243A (en) 1984-10-09 1989-12-05 Eli Lilly And Company Process for producing A-21978C derivatives
US4800157A (en) 1985-09-09 1989-01-24 Eli Lilly And Company Process for producing the A-21978C antibiotics
US4874843A (en) 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
ZA901622B (en) * 1989-03-06 1991-11-27 Lilly Co Eli An improved diluent formulation for daptomycin
FR2755857B1 (fr) * 1996-11-19 1998-12-24 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
FR2772272B1 (fr) * 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
DE122006000049I1 (de) 1998-09-25 2007-01-04 Cubist Pharm Inc Verwendung von Daptomycin
US9393093B2 (en) 2008-02-18 2016-07-19 Covidien Lp Clip for implant deployment device

Also Published As

Publication number Publication date
IS8807A (is) 2009-03-10
NL300232I1 (nl) 2006-09-01
RU2363489C2 (ru) 2009-08-10
PT1674107T (pt) 2016-12-07
CY2006003I1 (el) 2009-11-04
SI1115417T1 (sl) 2006-08-31
BR9914051A (pt) 2001-06-19
LU91254I2 (fr) 2006-08-28
RU2363489C9 (ru) 2010-03-20
DK1115417T3 (da) 2006-07-31
CN1530136A (zh) 2004-09-22
JP2002525335A (ja) 2002-08-13
EP1115417B1 (en) 2006-04-05
ATE322280T1 (de) 2006-04-15
JP2004339238A (ja) 2004-12-02
KR20010075327A (ko) 2001-08-09
DK1674107T3 (en) 2016-12-19
EP1674107A8 (en) 2006-10-04
HK1040363A1 (en) 2002-06-07
WO2000018419A3 (en) 2000-07-06
NO20011454L (no) 2001-05-25
EP1674107B1 (en) 2016-08-24
US6852689B2 (en) 2005-02-08
EP1674107A2 (en) 2006-06-28
JP4184607B2 (ja) 2008-11-19
NZ510690A (en) 2002-10-25
CY2006003I2 (el) 2009-11-04
CY1105556T1 (el) 2010-07-28
KR20100051735A (ko) 2010-05-17
HUP0103874A3 (en) 2002-09-30
PT1115417E (pt) 2006-07-31
PL206091B1 (pl) 2010-06-30
CY1118334T1 (el) 2017-06-28
EP1115417A2 (en) 2001-07-18
HUP0103874A2 (hu) 2002-02-28
DE122006000049I1 (de) 2007-01-04
PL203689B1 (pl) 2009-11-30
PL348328A1 (en) 2002-05-20
US20020142948A1 (en) 2002-10-03
TR200100841T2 (tr) 2002-01-21
EP1674107A3 (en) 2012-06-20
SI1674107T1 (sl) 2017-01-31
CN1348382A (zh) 2002-05-08
HK1040363B (zh) 2007-01-26
AU764348B2 (en) 2003-08-14
HU230656B1 (hu) 2017-06-28
DE69930758D1 (de) 2006-05-18
DE69930758T2 (de) 2007-04-26
IS5890A (is) 2001-03-14
NO20011454D0 (no) 2001-03-22
DE122006000049I2 (de) 2007-11-08
CA2344318A1 (en) 2000-04-06
JP2003321389A (ja) 2003-11-11
CN1150029C (zh) 2004-05-19
NL300232I2 (nl) 2007-01-02
AU6268799A (en) 2000-04-17
WO2000018419A2 (en) 2000-04-06
ES2259845T3 (es) 2006-10-16
RU2004106569A (ru) 2005-08-10
CA2344318C (en) 2006-07-04
EP1674107B8 (en) 2017-01-25
JP2006335773A (ja) 2006-12-14
US6468967B1 (en) 2002-10-22

Similar Documents

Publication Publication Date Title
ES2603086T3 (es) Uso de la daptomicina
NO955361L (no) Organiske aerogeler
BR0009016A (pt) Composição de apomorfina e sildenafil
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
ES2092890T3 (es) Aplicacion del riluzol en el tratamiento de la enfermedad de parkinson y de los sindromes de parkinson.
DK0586621T3 (da) Linsidomin til behandling af erektile dysfunktioner
PA8504401A1 (es) Compuestos farmaceuticamente activos
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
AR016798A1 (es) Uso de una cepa de lactobacillus para la elaboracion de un medicamento
CR9842A (es) Composiciones de celecoxib
EA200401317A1 (ru) Композиции и способы дозирования липосом определенных размеров для лечения или предотвращения заболевания
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
NO20032027L (no) Effektive antitumorbehandlinger
NO20055880L (no) Memantin orale doseringsformer
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
ES2083597T3 (es) Preparacion farmaceutica para el tratamiento del tiempo de coagulacion prolongado.
PT998287E (pt) Utilizacao de levobupivacaina
ES2184145T3 (es) Compuestos de acido sulfonico o sulfonilamino-n-(heteroaralquil)-azaheterociclilamida.
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
AR023185A1 (es) Tratamiento de cancer mejorado con temozolomida
GT200100089A (es) Combinacion de secretagogos de hormona de crecimiento y antidepresivos.
AR027394A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno